JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C000629200 on October 3, 2000

J. Biol. Chem., Vol. 275, Issue 47, 36847-36851, November 24, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/47/36847    most recent
C000629200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maemura, K.
Right arrow Articles by Lee, M.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maemura, K.
Right arrow Articles by Lee, M.-E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CLIF, a Novel Cycle-like Factor, Regulates the Circadian Oscillation of Plasminogen Activator Inhibitor-1 Gene Expression*

Koji MaemuraDagger §, Suzanne M. de la Monte, Michael T. ChinDagger , Matthew D. LayneDagger , Chung-Ming HsiehDagger , Shaw-Fang YetDagger , Mark A. PerrellaDagger ||, and Mu-En LeedaggerDagger

From the Dagger  Cardiovascular and the || Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 and the  Department of Medicine and Pathology, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903

Received for publication, September 8, 2000, and in revised form, October 3, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The onset of myocardial infarction occurs frequently in the early morning, and it may partly result from circadian variation of fibrinolytic activity. Plasminogen activator inhibitor-1 activity shows a circadian oscillation and may account for the morning onset of myocardial infarction. However, the molecular mechanisms regulating this circadian oscillation remain unknown. Recent evidence indicates that basic helix-loop-helix (bHLH)/PAS domain transcription factors play a crucial role in controlling the biological clock that controls circadian rhythm. We isolated a novel bHLH/PAS protein, cycle-like factor (CLIF) from human umbilical vein endothelial cells. CLIF shares high homology with Drosophila CYCLE, one of the essential transcriptional regulators of circadian rhythm. CLIF is expressed in endothelial cells and neurons in the brain, including the suprachiasmatic nucleus, the center of the circadian clock. In endothelial cells, CLIF forms a heterodimer with CLOCK and up-regulates the PAI-1 gene through E-box sites. Furthermore, Period2 and Cryptochrome1, whose expression show a circadian oscillation in peripheral tissues, inhibit the PAI-1 promoter activation by the CLOCK:CLIF heterodimer. These results suggest that CLIF regulates the circadian oscillation of PAI-1 gene expression in endothelial cells. In addition, the results potentially provide a molecular basis for the morning onset of myocardial infarction.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The onset of myocardial infarction occurs frequently in the early morning. It may result in part from the circadian variation of fibrinolytic activity. Plasminogen activator inhibitor-1 (PAI-1)1 is the major component of inhibitors of fibrinolysis activity. PAI-1 activity shows a clear circadian oscillation peaking in the early morning, and this may account for the morning onset of myocardial infarctions (1, 2). However, the molecular mechanisms regulating this circadian oscillation remain unknown.

Every organism from bacteria to humans has an internal biological clock that adapts its activity to a circadian rhythm. Recently, the molecular mechanisms underlying these circadian processes are beginning to be elucidated (3-5). The biological clock is composed of transcriptional-translational feedback loops (3). Many of these components, including CLOCK, CYCLE, and PERIOD (PER), belong to the basic helix-loop-helix (bHLH)/PAS domain family of transcription factors. Thus, the PAS domain plays a crucial role in regulating the biological clock (4). In mammals, CLOCK and BMAL1, the mammalian counterpart of Drosophila CYCLE, induce Per and Cryptochrome (Cry) gene expression (6). The PER and CRY proteins in turn act as negative components of the feedback loop by suppressing CLOCK:BMAL1-mediated transcription through CACGTG E-box enhancer elements (7, 8).

The central circadian pacemaker in mammals is localized in the hypothalamic suprachiasmatic nucleus (SCN) (4). Recent studies have shown circadian oscillations of various transcripts in both peripheral tissues and cultured cells. Their underlying rhythm is inferred to be due to the same mechanisms that are present in the SCN (9-11). These peripheral clocks are synchronized with the central clock by yet unidentified humoral factors (5, 10, 12-14). The functional significance of the mammalian peripheral clocks is unknown.

We report here the identification of a novel bHLH/PAS domain transcription factor, CLIF (cycle like factor) that shares high homology with Drosophila CYCLE. Since CLIF is expressed in vascular endothelial cells, we hypothesize that CLIF may regulate the circadian oscillation of PAI-1 gene expression in endothelial cells. We show that CLIF forms a heterodimer with CLOCK and in endothelial cells up-regulates the PAI-1 gene through its E-box sites. Furthermore, PER2 and CRY1, whose expression show a circadian oscillation in peripheral tissues, inhibit the PAI-1 promoter activation by the CLOCK:CLIF heterodimer. This may account for the circadian oscillation of PAI-1 gene expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Construction of Plasmids-- The endothelial PAS domain protein 1 (EPAS1) bait plasmid pBDGAL4-EPAS1 was constructed by amplification of cDNA encoding amino acids (aa) 30-380 of the human EPAS1 protein by the polymerase chain reaction (PCR). The amplified fragment was cloned into the vector pBDGAL4 Cam (Stratagene). The plasmids for GAL4 DNA binding domain fusion proteins were constructed by amplification of cDNAs encoding bHLH/PAS domain (ARNT, aa 70-508; BMAL1, aa 64-445; CLIF, aa 74-445) by PCR. The amplified fragments were cloned into pBDGAL4Cam. The plasmids for GAL4 activation domain fusion proteins were constructed by PCR amplification of cDNAs encoding EPAS1 or CLOCK. The amplified fragments were cloned into the yeast GAL4 activation domain vector, pADGAL4 (Stratagene). The phCLIF expression plasmid was constructed by PCR amplification of the full-length human CLIF cDNA using the primers 5'-TGAGAATTCGACCAAGTGGCTCCTGCGATG-3'and 5'-CAAGGATCCGAGGGTCCACTGGATGTCACT-3'. The amplified fragment was digested with EcoRI and BamHI and cloned in frame into pcDNA3.1(-)/Myc-HisA (Invitrogen). The mammalian expression vector for BMAL1 was made by PCR amplification of full-length BMAL1 and cloned into pcDNA3 (Invitrogen). The mammalian expression vectors for ARNT, CLOCK, PER2, and CRY1 are described elsewhere (6, 8, 15). The human PAI-1 promoter/luciferase reporter plasmids, p800LUC, p549LUC, and p187LUC, were gifts from David J. Loskutoff (16). E-boxes of the PAI-1 promoter were mutated at bp -677 to -672 (m1, CACGTG to GCTAGT) and at bp-562 to -557 (m2, CACGTG to TCGCTC) using the QuickChange site-directed mutagenesis kit (Stratagene). The authenticity of all constructs was verified by dideoxy chain termination sequencing.

Yeast Two-hybrid Screening-- A human umbilical vein endothelial cell (HUVEC) cDNA library was constructed by cloning HUVEC cDNAs into the vector HybriZAP-2.1 (Stratagene). The yeast strain YRG-2 (Stratagene) was made competent by the lithium acetate method (17). Approximately 1010 yeast cells were transformed with 100 µg of the EPAS1 bait plasmid pBDGAL4-EPAS1 and 100 µg of library plasmid. The screening and sequencing of positive clones were performed as described previously (18).

Construction of Recombinant Adenoviruses-- Recombinant adenovirus expressing CLIF (AdCMV.CLIF) was prepared by standard homologous recombination techniques using the replication-defective E1/E3-deleted serotype 5 human adenovirus (19). Adenovirus expressing CLOCK (AdCMV.CLOCK) was generated using the AdEasy system as described previously (20). In brief, the full-length mouse CLOCK cDNA was cloned into the shuttle vector pAdTrack-CMV. After recombination with the vector pAdEasy-1 in bacteria, high titer virus was generated in 293 cells and purified by cesium chloride ultracentrifugation. The titer of the purified adenovirus was determined in 293 cells by plaque assay techniques.

RNA Isolation and Northern Analysis-- Total RNA was prepared from mouse tissues and cultured cells with the RNeasy kit (QIAGEN). Northern analysis was performed as described previously (15). To obtain a probe for mouse CLIF, a fragment of the mouse CLIF cDNA was amplified by reverse transcriptase-PCR using primers based on the PAS domain sequences of the hCLIF cDNA (5'-AAGATGTTGCCAAAGTAAAGGA-3', 5'-ATTCCAGTTCTTTTGTCCAAGG-3'). The mouse CLIF cDNA shares 80.8% homology to hCLIF cDNA (data not shown).

In Situ Hybridization-- In situ hybridization studies were performed with paraffin sections as detailed previously (21, 22). Briefly, denatured, acetylated, and prehybridized tissue sections were hybridized for 12 h at 50 °C with 250 ng/ml of 14-biotin-UTP-labeled hCLIF antisense and sense cRNA probes. The hCLIF riboprobes were transcribed from a 447-bp (nucleotides 1600-2046) hCLIF cDNA fragment. After stringent washing and digestion of nonspecifically bound probe, the hybridized cRNAs were detected with VectorBrown substrate (Vector Laboratories). The sections were lightly counterstained with hematoxylin.

Gel Mobility Shift Assay-- Gel mobility shift assays were performed using in vitro translated proteins as described previously (15). The 32-bp double-stranded oligonucleotide probe (5'-CTGGACACGTGGGGAGACAATCACGTGGCTGG-3') contains the two E-boxes derived from the sequence of the PAI-1 promoter.

Transient Transfection Assays-- Bovine aortic endothelial cells (BAEC) were plated in six-well dishes and transfected with 15 ng of reporter construct and 1 µg of expression constructs using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's instructions. To correct for variation in transfection efficiency, we cotransfected 15 ng of pCMVbeta (CLONTECH) in all experiments. Cell extracts were prepared 48 h after transfection by a detergent lysis method (Promega). Luciferase activity and beta -galactosidase assays were performed as described previously (23). The ratio of luciferase activity to beta -galactosidase activity in each sample served as a measure of normalized luciferase activity. Each construct was transfected at least four times, and each transfection was done in triplicate. Data for each construct are presented as the mean ± S.E.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Yeast Two-hybrid Screening-- EPAS1 is a bHLH/PAS domain transcription factor that is expressed preferentially in vascular endothelial cells (24). To identify novel bHLH/PAS domain transcription factors in the cardiovascular system, we screened a HUVEC cDNA library by a yeast two-hybrid system using the HLH/PAS domain of EPAS1 as a bait. Eleven clones out of approximately 2 × 106 independent transformants were positive for both HIS3 and lacZ. Of the 11 positive clones, two represented overlapping cDNAs encoding the same novel bHLH/PAS domain protein. We screened a HUVEC cDNA lambda  phage library using this cDNA as a probe and obtained 10 additional clones for further analysis. The open reading frame encoded a novel polypeptide of 602 amino acids with a calculated molecular mass of 67 kDa. The putative initiation codon (GCGATGG) is in agreement with the Kozak consensus sequence.

Homology and Phylogenetic Analysis of CLIF-- Computer data base searches revealed that the amino acid sequence of this bHLH/PAS protein is homologous to Drosophila CYCLE and its mammalian homolog BMAL1 (44.1 and 44.9% identity, respectively) (25, 26). Thus we designated this novel bHLH/PAS protein as CLIF (CYCLE-like factor). The protein sequence alignment of hCLIF, hBMAL1, and Drosophila CYCLE revealed a particularly high degree of homology in the bHLH and PAS domains (Fig. 1A). Furthermore, a phylogenetic analysis within the ARNT superfamily revealed that CLIF and BMAL1 are most closely related to Drosophila CYCLE and diverge early from other members of the ARNT family (Fig. 1B). Since Drosophila CYCLE shows the highest homology to BMAL1 and CLIF with comparable identities, we conclude that CLIF is the second mammalian homolog of Drosophila CYCLE.


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 1.   Cloning of a novel bHLH/PAS domain transcription factor, CLIF. A, amino acid alignment of the deduced CLIF, hBMAL1, and Drosophila CYCLE. Alignment was performed using the Clustal V method. Identical (inverted) and similar (boxed) amino acids are indicated. B, phylogenetic analysis of CLIF. Phylogenetic analysis was performed based on the bHLH/PAS domain sequences with the Clustal V algorithm. The GenBankTM accession numbers for the sequences used in the phylogenetic analysis are: hCLIF, AF256215; hBMAL1, AB000812; mARNT3/BMAL1, AB014494; CYCLE, AF065473; mARNT2, D63644; mARNT, U10325; hARNT, M69238; dARNT, AB002556; zfBMAL1, AF144689; zfBMAL2, AF144691. C, CLIF interacts with EPAS1 and CLOCK. The yeast strain YRG-2 was transformed with plasmids encoding the indicated proteins in-frame with either the GAL4 DNA-binding domain (BD) or the GAL4 activation domain (AD). Binding between SV40 T antigen (T) and p53 was used as a control. Yeasts were harvested in mid-log phase, and quantitative beta -galactosidase assays were performed as described previously (18).

CLIF Specifically Interacts with EPAS1 and CLOCK-- BMAL1 is known to heterodimerize with both EPAS1 and CLOCK (27). To determine whether CLIF also interacts with EPAS1 and CLOCK, quantitative yeast beta -galactosidase assays were performed. Similar to BMAL1, CLIF interacted with EPAS1 and CLOCK, whereas ARNT interacted only with EPAS1 (Fig. 1C). This interaction of CLIF is specific because the combination of CLIF and other bHLH/PAS domain proteins, ARNT or BMAL1 was not sufficient to activate beta -galactosidase activity in yeast (data not shown).

Expression Pattern of CLIF in Adult Tissues-- To examine the expression pattern of CLIF, we performed Northern blot analysis on RNA isolated from human tissues. The human CLIF probe hybridized to four mRNAs of 8, 6, 2.4 and 2.2 kilobases. CLIF is expressed most abundantly in the brain and placenta, with lower expression in the heart, thymus, kidney, liver, and lung (Fig. 2A). In contrast to the restricted tissue distribution of CLIF, ARNT and BMAL1 were expressed in many tissues, including the brain, heart, and skeletal muscles as reported previously (Fig. 2A) (26, 27).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of CLIF mRNA in human tissues. A, Northern blot analysis of human tissues. A, a commercially prepared multiple-tissue Northern blot (CLONTECH) was hybridized with the indicated probes. To correct for differences in RNA loading, the filters were rehybridized with a radiolabeled actin probe. Abbreviations: B, brain; H, heart; Sk, skeletal muscle; C, colon; T, thymus; Sp, spleen; K, kidney; Li, liver; I, intestine; P, placenta; Lu, lung; Le, leukocyte. B, in situ hybridization analysis of CLIF expression in the human brain. Human brain sections were hybridized with hCLIF antisense and sense cRNA probes labeled with biotin. The in situ hybridization signals were detected with VectorBrown substrate. The sections were lightly counterstained with hematoxylin. Arrow, endothelial cells; arrowheads, neuronal cells in the SCN.

We further performed in situ hybridization on human tissues to identify the cellular expression of CLIF. CLIF was expressed in endothelial cells and neurons in the brain, including the SCN, i.e. the center of the circadian clock (Fig. 2B). We also detected CLIF mRNA transcripts in endothelial cells in the heart, lung, and kidney (data not shown). Additional analysis by gel mobility shift assays demonstrated that CLIF formed a heterodimer with CLOCK and bound to the E-box within the Per1 promoter (data not shown). Furthermore, transient transfection of CLOCK and CLIF together transactivated the Per-1 promoter to the same extent as CLOCK and BMAL1 (data not shown) (6). Taken together, CLIF as a heterodimerization partner of CLOCK may contribute to the control of circadian rhythm in both the central and peripheral clocks.

The endothelial cell regulation of vascular tone and fibrinolytic activity shows circadian variation (28, 29). For instance, the frequent onset of myocardial infarction during the early morning may partly result from the circadian variation of fibrinolytic activity (2, 30). In the basal state, PAI-1 is produced mainly in endothelial cells, with the highest activity in the early morning. This elevated PAI-1 activity corresponds with the peak occurrence of myocardial infarctions (31). Until now, the molecular mechanisms regulating this type of circadian rhythm have not been elucidated. We hypothesize that peripheral endothelial cells also contain a biological pacemaker and that CLOCK and CLIF are the critical components that activate genes with circadian variations such as PAI-1.

Circadian Expression of PAI-1 mRNA in Peripheral Organs-- To address this hypothesis, we first determined whether PAI-1 mRNA levels exhibited circadian variation. Indeed, Northern blot analysis of the mouse heart (Fig. 3A), kidney (Fig. 3B), brain, and lung (data not shown) showed circadian variation of PAI-1 mRNA levels with peak expression in the evening. This circadian oscillation pattern of mouse PAI-1 mRNA is antiphase to that of human PAI-1 activity, potentially due to the fact that rodents are nocturnal whereas humans are diurnal. To our knowledge, this is the first demonstration that the circadian oscillation of PAI-1 activity is regulated at mRNA level. The blots were then reprobed to analyze CLIF and BMAL1 expression in relation to PAI-1. These studies revealed that CLIF mRNA was constitutively expressed, whereas BMAL1 mRNA levels oscillated as reported previously (9) (Fig. 3C). The constant circadian expression pattern of CLIF is similar to that of Drosophila CYCLE (25). Per2 and Cry1 are important negative regulators of the biological clocks (32). Per2 and Cry1 expression followed a clear circadian oscillation (Fig. 3C). In these experiments, Clock was constitutively expressed as reported previously (data not shown) (33).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 3.   Circadian expression of PAI-1 mRNA in peripheral organs. A and B, circadian oscillation of PAI-1 mRNA levels. Eight-week-old male FVB mice were maintained in a 12 h light (7 a.m. to 7 p.m.) and 12 h dark (7 p.m. to 7 a.m.) cycles for 3 weeks. Total RNA (20 mg) from each tissue was used for Northern blot analysis, and RNA levels were quantified and normalized to 18 S rRNA for loading. The peak RNA expression was set as 100%. Upper panels, representative Northern blots; lower panels, normalized RNA levels (mean ± S.E.) from six independent experiments. Open bar, light cycle; filled bar, dark cycle. C, circadian oscillation of other biological pacemaker genes. The same blot used in B was hybridized with indicated probes. D, up-regulation of PAI-1 mRNA by CLOCK and CLIF. HUVECs were infected with AdCMV.GFP, AdCMV.CLOCK, or AdCMV.CLIF at the indicated multiplicity of infection (M.O.I.). Total RNA was isolated 48 h after infection. Northern blot analysis was performed using a human PAI-1 probe. The blot was hybridized with human CLOCK and CLIF probes to confirm their expression and with 18 S rRNA to normalize for loading.

Overexpression of Clock and CLIF Induce PAI-1 mRNA Expression-- We next examined whether the CLOCK:CLIF heterodimer is able to increase the endogenous PAI-1 mRNA in HUVEC. Using adenovirus-mediated gene transfer, we demonstrated that overexpression of CLOCK resulted in a dose-dependent increase in PAI-1 mRNA levels relative to the control cells infected with a GFP-expressing adenovirus (Fig. 3D). Coinfection of adenovirus expressing CLIF with CLOCK further increased the PAI-1 mRNA levels (Fig. 3D).

CLOCK and CLIF Transactivates the PAI-1 Promoter through the E-box Sites-- To further elucidate the mechanisms by which CLOCK and CLIF increase PAI-1 mRNA levels, we performed transient transfection assays using human PAI-1 promoter/luciferase reporter plasmids (16). Cotransfection of CLOCK and CLIF increased PAI-1 promoter activity by 5-fold (Fig. 4A). Deleting bp -800 to -550 of the PAI-1 promoter markedly diminished this induction by CLOCK and CLIF (Fig. 4B). Two E-box elements (CACGTG), which are the consensus binding sites of CLOCK and BMAL1 (6), are located at bp -677 to -672 and at bp -562 to -557. We generated point mutations in these E-boxes to determine whether they are important for the transactivation of PAI-1 promoter by CLOCK and CLIF. Indeed, mutation in either E-box decreased the transactivation of PAI-1 promoter (Fig. 4B). Mutation of both E-boxes nearly abolished the CLOCK and CLIF mediated transactivation (Fig. 4B). Thus, both E-box elements are important for the CLOCK:CLIF transactivation of the PAI-1 promoter.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   CLOCK and CLIF transactivate the PAI-1 promoter through two E-box sites. A, CLOCK and CLIF transactivate the PAI-1 promoter. The indicated expression plasmids (0.5 µg each) were cotransfected into BAEC with the PAI-1 promoter (-800 bp)/luciferase reporter plasmid. B, mutation of the E-boxes abolishes the transactivation of the PAI-1 promoter. The E-box at bp -677 to -672 was mutated from CACGTG to GCTAGT (m1), and the E-box at bp -562 to -557 was mutated from CACGTG to TCGCTC (m2). Deletion series of PAI-1 promoter (-549 and -187) or mutated PAI-1 promoter (m1, m2, and m1+2) reporter plasmids were transfected with the indicated expression plasmids. C, binding of CLOCK:CLIF heterodimer to the E-box of the PAI-1 gene. Gel mobility shift assays were performed as described under "Experimental Procedures" using the indicated in vitro translated proteins and a 32-bp double-stranded oligonucleotide (5'-CTGGACACGTGGGGAGACAATCACGTGGCTGG-3') probe containing the two E-boxes derived from the sequence of the PAI-1 promoter. Binding experiments were also performed in the presence of unlabeled E-box consensus oligonucleotide (E-Box) or unrelated nonspecific oligonucleotide (NS) at 100-fold molar excess. D, PER2 or CRY1 inhibits transactivation of the PAI-1 promoter by CLOCK:CLIF. The indicated expression plasmids (0.3 µg each) were cotransfected into BAEC with the PAI-1/luciferase reporter plasmid. A, B, and D, -fold induction represents the ratio (mean ± S.E.) of luciferase activity in cells transfected with expression plasmid to that in cells transfected with empty vector (pcDNA3).

To determine whether the CLOCK:CLIF heterodimer transactivates the PAI-1 promoter by directly binding to the E-boxes, we performed gel mobility shift assays with in vitro translated CLOCK and CLIF proteins and a labeled probe containing the PAI-1 E-boxes. In the presence of CLOCK, a weak shifted band was observed. In the presence of both CLOCK and CLIF proteins, however, robust DNA binding activity was detected (Fig. 4C).

PER2 or CRY1 Inhibits Transactivation of the PAI-1 Promoter by CLOCK:CLIF-- In the central circadian pacemaker, PER and CRY function by inhibiting CLOCK:BMAL1-mediated transcription of their own promoter through CACGTG E-box enhancer elements (7, 8). We found that Per2 and Cry1 mRNAs showed a clear circadian oscillation in peripheral tissues (Fig. 3B). Therefore, we asked whether PER2 or CRY1 could affect the CLOCK:CLIF activation of PAI-1. Cotransfection of PER2 partially inhibited CLOCK:CLIF-dependent transcription, while cotransfection of CRY1 abolished the induction of the PAI-1 promoter (Fig. 4D). These data suggest that PER2 and/or CRY1 suppress the CLOCK:CLIF-mediated transcription of PAI-1, resulting in the circadian oscillation of PAI-1 gene expression.

We identified that both E-boxes in PAI-1 promoter are responsible for its activation by CLOCK:CLIF. It is noteworthy that the E-box at bp -677 to -672 overlaps with the sequence of the 4G/5G polymorphism of the PAI-1 promoter, which correlates with serum levels of PAI-1 and the frequency of ischemic diseases (34, 35). Thus, the 4G/5G polymorphism of PAI-1 promoter may affect the binding of CLOCK:CLIF to this E-box or interaction with adjacent transcription factors, resulting in an altered circadian expression of the PAI-1 gene. Therefore, it may be interesting to see the relation between the circadian oscillation pattern of PAI-1 activity and the 4G/5G polymorphism.

Recent data indicate that the mammalian circadian system is hierarchically organized, with self-sustained oscillators in the SCN entraining dampened oscillators in the periphery (12). However, the physiological significance of these peripheral oscillators remains unknown. Our results suggest that a peripheral tissue pacemaker regulates the circadian expression of PAI-1 gene directly. There are two heterodimers containing CLOCK; BMAL1:CLOCK dimer and CLIF:CLOCK dimer. The oscillation pattern and distribution of these two dimers are different in peripheral tissues. Therefore it may be possible that the combination of CLOCK:CLIF or CLOCK:BMAL1 together with PER and CRY function to regulate the peripheral pacemakers differently. Thus circadian rhythm in mammals may be regulated by both the central and peripheral tissue pacemakers.

In addition, since PAI-1 plays a crucial role in controlling fibrinolytic activity, the results potentially provide a molecular basis for the circadian variation of myocardial infarction.

    ACKNOWLEDGEMENTS

We are grateful to Steven L. McKnight for the EPAS1 cDNA, to David J. Loskutoff for the PAI-1 reporter plasmids, and to Nicholas Gekakis and Charles J. Weitz for the expression plasmids for CLOCK, Per2, and Cry1. We thank Bonna Ith for technical assistance.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL 03745 (to M. T. C.), HL 10113 (to M. D. L.), HL 60788 (to M. A. P.), and HL 57664 (to M.-E. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF256215.

dagger Deceased on April 10, 2000.

§ To whom correspondence should be addressed: Dept. of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. Fax: 81-3-5800-8824; E-mail: kmae-tky@umin. ac.jp.

Published, JBC Papers in Press, October 3, 2000, DOI 10.1074/jbc.C000629200

    ABBREVIATIONS

The abbreviations used are: PAI-1, plasminogen activator inhibitor-1; EPAS1, endothelial PAS domain protein 1; CLIF, cycle-like factor; bHLH, basic helix-loop-helix; aa, amino acids; SCN, suprachiasmatic nucleus; HUVEC, human umbilical vein endothelial cell(s); BAEC, bovine aortic endothelial cell(s); PCR, polymerase chain reaction; bp, base pair(s); BCIP/NBT, 4-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Muller, J. E., Stone, P. H., Turi, Z. G., Rutherford, J. D., Czeisler, C. A., Parker, C., Poole, W. K., Passamani, E., Roberts, R., Robertson, T., Sobel, B. E., Willerson, J. T., Braunwald, E., and the MILLIS study group. (1985) N. Engl. J. Med. 313, 1315-1322
2. Braunwald, E. (1995) Circulation 91, 1604-1606
3. Dunlap, J. C. (1999) Cell 96, 271-290
4. Sassone-Corsi, P. (1998) Nature 392, 871-874
5. Schibler, U. (2000) Nature 404, 25-28
6. Gekakis, N., Staknis, D., Nguyen, H. B., Davis, F. C., Wilsbacher, L. D., King, D. P., Takahashi, J. S., and Weitz, C. J. (1998) Science 280, 1564-1569
7. Kume, K., Zylka, M. J., Sriram, S., Shearman, L. P., Weaver, D. R., Jin, X., Maywood, E. S., Hastings, M. H., and Reppert, S. M. (1999) Cell 98, 193-205
8. Griffin, E. A., Jr., Staknis, D., and Weitz, C. J. (1999) Science 286, 768-771
9. Oishi, K., Sakamoto, K., Okada, T., Nagase, T., and Ishida, N. (1998) Biochem. Cell Biol. Commun. 253, 199-203
10. Oishi, K., Sakamoto, K., Okada, T., Nagase, T., and Ishida, N. (1998) Neurosci. Lett. 256, 117-119
11. Balsalobre, A., Damiola, F., and Schibler, U. (1998) Cell 93, 929-937
12. Yamazaki, S., Numano, R., Abe, M., Hida, A., Takahashi, R., Ueda, M., Block, G. D., Sakaki, Y., Menaker, M., and Tei, H. (2000) Science 288, 682-685
13. Sakamoto, K., Nagase, T., Fukui, H., Horikawa, K., Okada, T., Tanaka, H., Sato, K., Miyake, Y., Ohara, O., Kako, K., and Ishida, N. (1998) J. Biol. Chem. 273, 27039-27042
14. Brown, S. A., and Schibler, U. (1999) Curr. Opin. Genet. Dev. 9, 588-594
15. Maemura, K., Hsieh, C.-M., Jain, M. K., Fukumoto, S., Layne, M. D., Liu, Y., Kourembanas, S., Yet, S.-F., Perrella, M. A., and Lee, M.-E. (1999) J. Biol. Chem. 274, 31565-31570
16. van Zonneveld, A. J., Curriden, S. A., and Loskutoff, D. J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 5525-5529
17. Schiestl, R. H., and Gietz, R. D. (1989) Curr. Genet. 16, 339-346
18. Chin, M. T., Maemura, K., Fukumoto, S., Jain, M. K., Layne, M. D., Watanabe, M., Hsieh, C.-M., and Lee, M.-E. (2000) J. Biol. Chem. 275, 6381-6387
19. Herz, J., and Gerard, R. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2812-2816
20. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2509-2514
21. de la Monte, S. M., and Bloch, K. D. (1997) Mol. Chem. Neuropathol. 30, 139-159
22. de la Monte, S. M., Ng, S. C., and Hsu, D. W. (1995) Am. J. Pathol. 147, 934-946
23. Yoshizumi, M., Hsieh, C.-M., Zhou, F., Tsai, J. C., Patterson, C., Perrella, M. A., and Lee, M.-E. (1995) Mol. Cell. Biol. 15, 3266-3272
24. Tian, H., McKnight, S. L., and Russell, D. W. (1997) Genes Dev. 11, 72-82
25. Rutila, J. E., Suri, V., Le, M., So, W. V., Rosbash, M., and Hall, J. C. (1998) Cell 93, 805-814
26. Ikeda, M., and Nomura, M. (1997) Biochem. Cell Biol. Commun. 233, 258-264
27. Hogenesch, J. B., Gu, Y. Z., Jain, S., and Bradfield, C. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5474-5479
28. Guney, H. Z., Uluoglu, C., Hodoglugil, U., Gorgun, C. Z., Yamanoglu, T. M., Abacioglu, N., and Zengil, H. (1999) Chronobiol. Int. 16, 779-787
29. Adreotti, F., and Kluft, C. (1991) Chronobiol. Int. 8, 336-351
30. Kurnik, P. B. (1996) Cardiol. Clin. 14, 251-262
31. Angleton, P., Chandler, W. L., and Schmer, G. (1989) Circulation 79, 101-106
32. Shearman, L. P., Sriram, S., Weaver, D. R., Maywood, E. S., Chaves, I., Zheng, B., Kume, K., Lee, C. C., van der Horst, G. T., Hastings, M. H., and Reppert, S. M. (2000) Science 288, 1013-1019
33. Sun, Z. S., Albrecht, U., Zhuchenko, O., Bailey, J., Eichele, G., and Lee, C. C. (1997) Cell 90, 1003-1011
34. Eriksson, P., Kallin, B., van't Hooft, F. M., Bavenholm, P., and Hamsten, A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1851-1855
35. Roest, M., van der Schouw, Y. T., Banga, J. D., Tempelman, M. J., de Groot, P. G., Sixma, J. J., and Grobbee, D. E. (2000) Circulation 101, 67-70


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
H. Sei, K. Oishi, S. Chikahisa, K. Kitaoka, E. Takeda, and N. Ishida
Diurnal Amplitudes of Arterial Pressure and Heart Rate Are Dampened in Clock Mutant Mice and Adrenalectomized Mice
Endocrinology, July 1, 2008; 149(7): 3576 - 3580.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. J. Westgate, Y. Cheng, D. F. Reilly, T. S. Price, J. A. Walisser, C. A. Bradfield, and G. A. FitzGerald
Genetic Components of the Circadian Clock Regulate Thrombogenesis In Vivo
Circulation, April 22, 2008; 117(16): 2087 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Kunieda, T. Minamino, K. Miura, T. Katsuno, K. Tateno, H. Miyauchi, S. Kaneko, C. A. Bradfield, G. A. FitzGerald, and I. Komuro
Reduced Nitric Oxide Causes Age-Associated Impairment of Circadian Rhythmicity
Circ. Res., March 14, 2008; 102(5): 607 - 614.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Takeda, K. Maemura, S. Horie, K. Oishi, Y. Imai, T. Harada, T. Saito, T. Shiga, E. Amiya, I. Manabe, et al.
Thrombomodulin Is a Clock-controlled Gene in Vascular Endothelial Cells
J. Biol. Chem., November 9, 2007; 282(45): 32561 - 32567.
[Abstract] [Full Text] [PDF]


Home page
J Biol RhythmsHome page
T. Kudo, T. Tamagawa, M. Kawashima, N. Mito, and S. Shibata
Attenuating Effect of Clock Mutation on Triglyceride Contents in the ICR Mouse Liver under a High-Fat Diet
J Biol Rhythms, August 1, 2007; 22(4): 312 - 323.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. F. Reilly, E. J. Westgate, and G. A. FitzGerald
Peripheral Circadian Clocks in the Vasculature
Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1694 - 1705.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
J. Dong, S. Fujii, S. Imagawa, S. Matsumoto, M. Matsushita, S. Todo, H. Tsutsui, and B. E. Sobel
IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBP{delta}
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C209 - C215.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Wang, L. Yin, and M. A. Lazar
The Orphan Nuclear Receptor Rev-erb{alpha} Regulates Circadian Expression of Plasminogen Activator Inhibitor Type 1
J. Biol. Chem., November 10, 2006; 281(45): 33842 - 33848.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Fujita, M. Kang, M. Eren, L. A. Gleaves, D. E. Vaughan, and T. Kume
Foxc2 Is a Common Mediator of Insulin and Transforming Growth Factor {beta} Signaling to Regulate Plasminogen Activator Inhibitor Type I Gene Expression
Circ. Res., March 17, 2006; 98(5): 626 - 634.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Kunieda, T. Minamino, T. Katsuno, K. Tateno, J.-i. Nishi, H. Miyauchi, M. Orimo, S. Okada, and I. Komuro
Cellular Senescence Impairs Circadian Expression of Clock Genes In Vitro and In Vivo
Circ. Res., March 3, 2006; 98(4): 532 - 539.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Koyanagi, S. Okazawa, Y. Kuramoto, K. Ushijima, H. Shimeno, S. Soeda, H. Okamura, and S. Ohdo
Chronic Treatment with Prednisolone Represses the Circadian Oscillation of Clock Gene Expression in Mouse Peripheral Tissues
Mol. Endocrinol., March 1, 2006; 20(3): 573 - 583.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. E. Young
The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H1 - H16.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
J.-F. Marion, C. Yang, A. Caqueret, F. Boucher, and J. L. Michaud
Sim1 and Sim2 are required for the correct targeting of mammillary body axons
Development, December 15, 2005; 132(24): 5527 - 5537.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
S. Masuki, T. Todo, Y. Nakano, H. Okamura, and H. Nose
Reduced {alpha}-adrenoceptor responsiveness and enhanced baroreflex sensitivity in Cry-deficient mice lacking a biological clock
J. Physiol., July 1, 2005; 566(1): 213 - 224.
[Abstract] [Full Text] [PDF]


Home page
J Biol RhythmsHome page
C. Bertolucci, M. Pinotti, I. Colognesi, A. Foa, F. Bernardi, and F. Portaluppi
Circadian Rhythms in Mouse Blood Coagulation
J Biol Rhythms, June 1, 2005; 20(3): 219 - 224.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Pinotti, C. Bertolucci, F. Portaluppi, I. Colognesi, E. Frigato, A. Foa, and F. Bernardi
Daily and Circadian Rhythms of Tissue Factor Pathway Inhibitor and Factor VII Activity
Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 646 - 649.
[Abstract] [Full Text] [PDF]


Home page
DNA ResHome page
K. Oishi, N. Amagai, H. Shirai, K. Kadota, N. Ohkura, and N. Ishida
Genome-wide Expression Analysis Reveals 100 Adrenal Gland-dependent Circadian Genes in the Mouse Liver
DNA Res, January 1, 2005; 12(3): 191 - 202.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
D. J. Kennaway
The role of circadian rhythmicity in reproduction
Hum. Reprod. Update, January 1, 2005; 11(1): 91 - 101.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Kudo, E. Nakayama, S. Suzuki, M. Akiyama, and S. Shibata
Cholesterol diet enhances daily rhythm of Pai-1 mRNA in the mouse liver
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E644 - E651.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Takeda, K. Maemura, Y. Imai, T. Harada, D. Kawanami, T. Nojiri, I. Manabe, and R. Nagai
Endothelial PAS Domain Protein 1 Gene Promotes Angiogenesis Through the Transactivation of Both Vascular Endothelial Growth Factor and Its Receptor, Flt-1
Circ. Res., July 23, 2004; 95(2): 146 - 153.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Yang, F. Boucher, A. Tremblay, and J. L. Michaud
Regulatory Interaction between Arylhydrocarbon Receptor and SIM1, Two Basic Helix-Loop-Helix PAS Proteins Involved in the Control of Food Intake
J. Biol. Chem., March 5, 2004; 279(10): 9306 - 9312.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
T. Okano and Y. Fukada
Chicktacking Pineal Clock
J. Biochem., December 1, 2003; 134(6): 791 - 797.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. C. Chang, H. G. McWatters, J. A. Williams, A. L. Gotter, J. D. Levine, and S. M. Reppert
Constructing a Feedback Loop with Circadian Clock Molecules from the Silkmoth, Antheraea pernyi
J. Biol. Chem., October 3, 2003; 278(40): 38149 - 38158.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
D.J. Kennaway, T.J. Varcoe, and V.J. Mau
Rhythmic expression of clock and clock-controlled genes in the rat oviduct
Mol. Hum. Reprod., September 1, 2003; 9(9): 503 - 507.
[Abstract] [Full Text] [PDF]


Home page